ScholarLens Back to search
2016•Recent Patents on Anti-Cancer Drug DiscoveryRequires access

Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents

Jinzheng Wang, Xiaoan Wen, Jun Liu, Hongbin Sun

Open publisher page 4 citations

Abstract

Recent studies show that enhanced mitochondrial biogenesis can "fuel" the cancer cells to grow and migrate. It is therefore proposed that inhibiting the mitochondrial biogenesis could be a new approach to cancer therapy. This review summarizes recent patents and papers in the development of small molecule inhibitors of key regulators responsible for tumor mitochondrial biogenesis, including PPARγcoactivator-1α(PGC-1α), PPARγcoactivator-1β, estrogen-related receptor family (ERRs), estrogen receptor α(ERα), mammalian target of rapamycin, c-Myc and PPARs.

About this research paper

What this paper is about

Recent studies show that enhanced mitochondrial biogenesis can "fuel" the cancer cells to grow and migrate. It is therefore proposed that inhibiting the mitochondrial biogenesis could be a new approach to cancer therapy. This review summarizes recent patents and papers in the development of small molecule inhibitors of key regulators responsible for tumor mitochondrial biogenesis, including PPARγcoactivator-1α(PGC-1α), PPARγcoactivator-1β, estrogen-related receptor family (ERRs), estrogen receptor α(ERα), mammalian target of rapamycin, c-Myc and PPARs.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Recent studies show that enhanced mitochondrial biogenesis can "fuel" the cancer cells to grow and migrate. It is therefore proposed that inhibiting the mitochondrial biogenesis could be a new approach to cancer therapy. This review summarizes recent patents and papers in the development of small molecule inhibitors of key regulators responsible for tumor mitochondrial biogenesis, including PPARγcoactivator-1α(PGC-1α), PPARγcoactivator-1β, estrogen-related receptor family (ERRs), estrogen receptor α(ERα), mammalian target of rapamycin, c-Myc and PPARs.

Key concepts: Mitochondrial biogenesis, Coactivator, Biogenesis, Cancer research, Organelle biogenesis, Biology, Mitochondrion, Cell biology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents — Research Paper | ScholarLens